Prognostic value of FDG-PET indices for the assessment of histological response to neoadjuvant chemotherapy and outcome in pediatric patients with Ewing sarcoma and osteosarcoma

Bailly, Clément; Leforestier, Rodolphe; Campion, Loı̈c; Thébaud, Estelle; Moreau, A; Kraeber‐Bodéré, Françoise; Carlier, Thomas; Bodet-Milin, Caroline

doi:10.1371/journal.pone.0183841

Cited by 24 publications

(22 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With growing research on fluorodeoxyglucose (FDG) PET-CT in cancer management, these molecular response criteria have shown promises in prognostication and for response assessment in comparison to standard morphological criteria. [192021] One study comparing EORTC criteria to PERCIST for response evaluation by FDG PET/CT in metastatic colorectal cancer treated with irinotecan and cetuximab had showed similar response and good agreement (Kappa coefficient-0.76). [22] However, large randomized trials are lacking comparing these molecular criteria to morphological criteria.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of response in patients of metastatic castration resistant prostate cancer undergoing systemic radiotherapy with lutetium177-prostate-specific membrane antigen: A comparison between response evaluation criteria in solid tumors, positron-emission tomography response criteria in solid tumors, European organization for research and treatment of cancer, and MDA criteria assessed by gallium 68-prostate-specific membrane antigen positron-emission tomography-computed tomography

et al. 2019

View full text Add to dashboard Cite

Introduction: We evaluated various morphological and molecular response criteria in metastatic castration-resistant prostate cancer (PCa) patient undergoing peptide receptor radioligand therapy (PRLT) with Lutetium177-prostate-specific membrane antigen (PSMA) by using Gallium 68-PSMA positron-emission tomography-computed tomography (Ga68-PSMA PET-CT). Methods: A total of 46 pre- and 8–12 weeks’ post-PRLT Ga68-PSMA PET-CT studies were reanalyzed (23 comparisons). Prostate-specific antigen drop of ≥50% and ≥25% increase was considered as partial response (PR) and progressive disease (PD), respectively, for biochemical response (BR) while change in-between was considered as stable disease (SD). Response evaluation criteria in solid tumors 1.1 (RECIST 1.1) and MD Anderson (MDA) criteria for morphological response while PET response criteria in solid tumors 1.0 (PERCIST 1.0) and European organization for research and treatment of cancer (EORTC) criteria for molecular response were used. Kappa coefficient was derived to see the level of agreement. Results: The proportion of PD, PR, and SD by BR and RECIST criteria was 9 (39.13%), 3 (13.04%), and 11 (47.83%) and 5 (21.74%), 2 (8.70%), and 16 (69.57%), respectively. The proportion of PD, PR, and SD was same by PERCIST and EORTC criteria and which were 8 (34.78%), 5 (21.74%), and 10 (43.48%). The proportion of PD, PR, and SD by MDA criteria was 1 (4.35%), 1 (4.35%), and 21 (91.30%), respectively. Poor agreement between BR and both morphological criteria while a statistically significant agreement with both molecular criteria seen. Conclusion: We concluded that molecular criteria performed better than morphological criteria in response assessment by Ga68-PSMA PET-CT in metastatic castration resistant PCa patients undergoing PRLT.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of response in patients of metastatic castration resistant prostate cancer undergoing systemic radiotherapy with lutetium177-prostate-specific membrane antigen: A comparison between response evaluation criteria in solid tumors, positron-emission tomography response criteria in solid tumors, European organization for research and treatment of cancer, and MDA criteria assessed by gallium 68-prostate-specific membrane antigen positron-emission tomography-computed tomography

et al. 2019

View full text Add to dashboard Cite

show abstract

“…We collected 47 publications on “Other” cancer types. This category included studies on gastrointestinal (11) [ 257 , 258 , 259 , 260 , 261 , 262 , 263 , 264 , 265 , 266 , 267 ], pancreatic (8) [ 268 , 269 , 270 , 271 , 272 , 273 , 274 , 275 ], sarcoma (8) [ 276 , 277 , 278 , 279 , 280 , 281 , 282 , 283 ], neuroendocrine (5) [ 284 , 285 , 286 , 287 , 288 ], prostate (4) [ 289 , 290 , 291 , 292 ], thyroid (3) [ 293 , 294 , 295 ], thymic (2) [ 296 , 297 ], skin (2) [ 298 , 299 ], liver (2) [ 300 , 301 ], and renal carcinomas (1) [ 302 ]. The average number of patients was 84 (median = 70, range, 26–214) and the average number of textural features extracted was 29 (median = 17, ...…”

Section: Resultsmentioning

confidence: 99%

A Systematic Review of PET Textural Analysis and Radiomics in Cancer

et al. 2021

View full text Add to dashboard Cite

Background: Although many works have supported the utility of PET radiomics, several authors have raised concerns over the robustness and replicability of the results. This study aimed to perform a systematic review on the topic of PET radiomics and the used methodologies. Methods: PubMed was searched up to 15 October 2020. Original research articles based on human data specifying at least one tumor type and PET image were included, excluding those that apply only first-order statistics and those including fewer than 20 patients. Each publication, cancer type, objective and several methodological parameters (number of patients and features, validation approach, among other things) were extracted. Results: A total of 290 studies were included. Lung (28%) and head and neck (24%) were the most studied cancers. The most common objective was prognosis/treatment response (46%), followed by diagnosis/staging (21%), tumor characterization (18%) and technical evaluations (15%). The average number of patients included was 114 (median = 71; range 20–1419), and the average number of high-order features calculated per study was 31 (median = 26, range 1–286). Conclusions: PET radiomics is a promising field, but the number of patients in most publications is insufficient, and very few papers perform in-depth validations. The role of standardization initiatives will be crucial in the upcoming years.

show abstract

“…TVR may not adequately reflect the complex histological changes resulting from response to chemotherapy. Therefore, besides TVR, also the residual extramedullary tumor volume, calcification of residual tumor in soft tissue and medullary cavity, T2 signal variations, diffusion weighted imaging, and fludeoxyglucose positron emission tomography have been investigated as potential markers for response . Taking also (some of) these factors into account, a better prediction of tumor response in early induction might be possible.…”

Section: Discussionmentioning

confidence: 99%

The relation of radiological tumor volume response to histological response and outcome in patients with localized Ewing Sarcoma

et al. 2019

View full text Add to dashboard Cite

Background Magnetic resonance imaging (MRI) is the modality of choice for local staging and response evaluation of Ewing sarcoma (EwS). Aim of this study was to determine the relevance of tumor volume response (TVR) in relation to histological response (HisRes) and survival, in order to evaluate if early modification of chemotherapy might be indicated in patients with inadequate TVR. Methods Three dimensional (3D)‐tumor volume data at diagnosis, during early induction phase (1‐3 courses of chemotherapy; n = 195) and/or late induction phase (4‐6 courses; n = 175) from 241 localized patients were retrospectively analyzed. A distinction was made between adequate response (reduction ≥67%) and inadequate response (reduction <67% or progression). Correlations between TVR, HisRes, event free survival (EFS), and overall survival (OS) were analyzed using chi‐square tests, log‐rank tests, and the Cox‐regression model. Results Early adequate TVR, noted in 41% of patients, did not correlate with EFS (P = 0.92) or OS (P = 0.38). During late induction phase 62% of patients showed an adequate TVR. EFS for patients with late adequate TVR was better (78%) than for those with inadequate late TVR (61%) (P = 0.01); OS was 80% and 69% (P = 0.26), respectively. No correlation was found between TVR and HisRes. Multivariate analysis showed that poor HisRes, pelvic location and late inadequate TVR were associated with poor outcome. Conclusions Early inadequate TVR does not predict adverse outcome; therefore, changing the treatment to second line chemotherapy is not indicated in case of inadequate early TVR. Late adequate TVR and good HisRes correlate with better EFS; patients with late inadequate TVR might benefit from augmented therapy.

show abstract

Prognostic value of FDG-PET indices for the assessment of histological response to neoadjuvant chemotherapy and outcome in pediatric patients with Ewing sarcoma and osteosarcoma

Cited by 24 publications

References 33 publications

A Systematic Review of PET Textural Analysis and Radiomics in Cancer

The relation of radiological tumor volume response to histological response and outcome in patients with localized Ewing Sarcoma

Contact Info

Product

Resources

About